Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

At the time of data cutoff, 71% of patients achieved a complete response following treatment.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

At the end of the induction phase, 86% of patients had achieved a complete response.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

The observational LOBSTER study has already enrolled 303 patients and collected 479 samples.

Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.